The European Medicines Agency's Committee for Medicinal Products for Human Use said Friday it's recommending a marketing authorization for Viatris' (VTRS) emtricitabine/tenofovir alafenamide to treat adults and adolescents with human immunodeficiency virus type 1, or HIV-1.
The committee said the medicine is a generic of Descovy, which has been authorized in the EU since April 2016.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.